Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

statings

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s leukaemia drug Besponsa

Firm plans to appeal the final appraisal determination on its orphan drug

- PMLiVE

NICE expands Merck KGaA’s Erbitux reach

Backs the medicines use for patients with SCCHN

- PMLiVE

Bayer’s Nexavar backed by NICE for liver cancer

The drug is the only approved first-line treatment for advanced HCC

Gilead Sciences

People at-risk of HIV in England could get PrEP from September

10,000 people will use Gilead’s Truvada in the upcoming trial

UK flag

UK appoints pharma veteran to ‘streamline’ NHS costs

Steve Oldfield will take up new chief commercial officer role at the Department of Health

- PMLiVE

NICE backs Cancer Drugs Fund support for Roche’s Gazyvaro

Lymphoma treatment will be used in conjunction with chemotherapy

Launch of the HSJ Partnership Awards: a programme for inspirational organisations helping to transform the NHS

New Awards will recognise the many private sector organisations who partner with the NHS to deliver improved patient outcomes and cost-effective care

Wilmington Healthcare

- PMLiVE

NICE backs Teva’s Cinqaero for severe asthma

Ruling will allow it to compete with GSK's rival IL-5 inhibitor Nucala

Tackling the challenge of non-adherence

Improving compliance requires empowering patients to be active partners in their own care

- PMLiVE

NICE gives green light to Ipsen’s Cabometyx

Backs the medicine’s use for patients with advanced kidney cancer

- PMLiVE

UK pharma launches legal challenge to NICE plans

Applies for judicial review of budget impact test

- PMLiVE

NICE broadens access to Alexion’s rare disease drug Strensiq

New deal offers NHS England a discount for the drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links